CompletedNCT01248195
Comparing Treatment Options for Schizophrenia in Europe
About this title
Read the official source — NCT01248195Medication studyAges 18–40Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 40 years.
- Listed locations
- Melbourne and 25 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMay 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 479
- Sponsor
- Rene Kahn
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Australia, France, United Kingdom, ...
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT01248195
- Official title
Show the full official title
Optimization of Treatment and Management of Schizophrenia in Europe
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Melbourne, Australia · Innsbruck, Austria · Leuven, Belgium
20 more locations
- Sofia, Bulgaria
- Prague, Czechia
- Hradec Králové, Czechia
- Glostrup Municipality, Denmark
- Créteil, France
- Halle, Germany
- Mannheim, Germany
- München, Germany
- Tel HaShomer, Israel
- Naples, Italy
- Utrecht, Netherlands
- Poznan, Poland
- Bucharest, Romania
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Oetwil, Switzerland
- London, United Kingdom
- Manchester, United Kingdom
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Rene Kahn.
Did this study involve medication?
Yes. The study involved medication, including Amisulpride open label, 6-week amisulpride double blind treatment, 6-week olanzapine double blind treatment and 12-week clozapine open-label treatment.
Who was this study for?
Listed age limits: 18 years to 40 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia